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Abstract
Background: Major depression is a serious mood disorder affecting millions of adults and children worldwide.
While the etiopathology of depression remains obscure, antidepressant medications increase synaptic levels of
monoamine neurotransmitters in brain regions associated with the disease. Monoamine transmitters activate
multiple signaling cascades some of which have been investigated as potential mediators of depression or
antidepressant drug action. However, the diacylglycerol arm of phosphoinositide signaling cascades has not been
systematically investigated, even though downstream targets of this cascade have been implicated in depression.
With the ultimate goal of uncovering the primary postsynaptic actions that may initiate cellular antidepressive
signaling, we have examined the antidepressant-induced production of CDP-diacylglycerol which is both a product
of diacylglycerol phosphorylation and a precursor for the synthesis of physiologically critical glycerophospholipids
such as the phosphatidylinositides. For this, drug effects on [3H]cytidine-labeled CDP-diacylglycerol and
[3H]inositol-labeled phosphatidylinositides were measured in response to the tricyclics desipramine and
imipramine, the selective serotonin reuptake inhibitors fluoxetine and paroxetine, the atypical antidepressants
maprotiline and nomifensine, and several monoamine oxidase inhibitors.
Results: Multiple compounds from each antidepressant category significantly stimulated [3H]CDP-diacylglycerol
accumulation in cerebrocortical, hippocampal, and striatal tissues, and also enhanced the resynthesis of inositol
phospholipids. Conversely, various antipsychotics, anxiolytics, and non-antidepressant psychotropic agents failed
to significantly induce CDP-diacylglycerol or phosphoinositide synthesis. Drug-induced CDP-diacylglycerol
accumulation was independent of lithium and only partially dependent on phosphoinositide hydrolysis, thus
indicating that antidepressants can mobilize CDP-diacylglycerol from additional pools lying outside of the inositol
cycle. Further, unlike direct serotonergic, muscarinic, or α-adrenergic agonists that elicited comparable or lower
effects on CDP-diacylglycerol versus inositol phosphates, the antidepressants dose-dependently induced
significantly greater accumulations of CDP-diacylglycerol.
Conclusion: Chemically divergent antidepressant agents commonly and significantly enhanced the accumulation
of CDP-diacylglycerol. The latter is not only a derived product of phosphoinositide hydrolysis but is also a crucial
intermediate in the biosynthesis of several signaling substrates. Hence, altered CDP-diacylglycerol signaling might
be implicated in the pathophysiology of depression or the mechanism of action of diverse antidepressant
medications.
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Background
Major depression is an increasingly prevalent mood disorder that afflicts millions of people worldwide [1-3]. While
a number of medications is available for managing the
disease symptoms, the mechanism of action of current
antidepressants is not well understood [4,5]. It is known,
however, that antidepressant medications generally
increase the synaptic levels of the monoamine neurotransmitters serotonin, norepinephrine, and/or dopamine in
discrete brain regions [6,7]. The monoamines are then
thought to activate their cognate postsynaptic receptors
and modulate the activities of downstream signaling cascades to produce the antidepressive effect [5,8-10].
Monoamine receptors coupled to diverse signaling cascades, including those mediated through adenylyl cyclase,
phospholipases, and MAP Kinases [11-14]. Aspects of
each signaling system have been investigated as potential
downstream targets of antidepressive mechanisms with
multiple and sometimes divergent findings [8,15,16]. As
examples, acute or chronic treatment with various antidepressant compounds can lead to changes in basal or druginduced activities of brain adenylyl cyclase [17-20], phospholipase A2 [21], CREB [22,23], phosphoinositide-specific phospholipase C (PLC) [15,24,25], inositol
phosphates (IPs) [26-29], phosphatidylinositides (PI)
[29,30], protein kinase C (PKC) [31-33], extracellular signal regulated kinase [16,34], ion channels [35,36], neurotrophins [37-39], and various neuropeptides [40-42].
Antidepressants can also enhance neurogenesis [43-46],
modulate neuronal excitability [47-49], and alter the gene
expression of various signaling components including
neurotransmitter transporters, receptors, transducers, and
effectors [50-53]. While these observations suggest that
changes in postsynaptic signaling cascades may constitute
an integral component in the mechanisms that underlie
depression or its treatment with antidepressant medications, no signaling cascade has been identified that adequately explains the behavioral and clinical data.
The PI-related observations in particular have been corroborated by clinical studies showing that depressed persons may have reduced cortical levels of the PI precursor
myo-inositol [54,55]. Moreover, oral ingestion of bolus
doses of myo-inositol could elicit antidepressive responses
in rodents [56,57], and enhance the recovery of clinically
depressed patients [58]. Consistent with these findings,
chronic administration of antidepressant agents has been
associated with increased levels of the PIs in human platelets [29,30]. These observations suggest that alterations in
the PI signaling pathway may be implicated in the pathophysiology of depression and/or the mode of action of
antidepressant agents [5,25,59,60].
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Several past studies examined IP signaling, but not the status of diacylglycerol (DG) production or signaling, as a
potential target of disease pathology or pharmacological
treatment with antidepressants [31-33]. Diacylglycerol
signaling is important because this lipid is the endogenous regulator of PKC activity, and the latter is one of the
indices shown to be altered in depressed persons [3133,61]. Moreover, PLC-stimulating receptors show differences in their capacity to generate diacylglycerol (relative
to IP) from phospholipid hydrolysis [62,63]. Therefore, to
the extent that PI signaling or PKC activity may be
involved in antidepressant drug action, it should be
important to clarify the specific effects of the agents on
diacylglycerol production as a potential basis for their
therapeutic efficacy. Following our previously reported
preliminary observations [64], we have now examined
antidepressant drug effects on cellular diacylglycerol production and metabolism, including the resynthesis of the
PI substrates. The results show that antidepressants
belonging to diverse chemical and pharmacological
classes acutely increase the formation of CDP-diacylglycerol (CDP-DG), a metabolic derivative of diacylglycerol,
and that this effect does translate to enhanced resynthesis
of the PIs. The latter are physiologically critical not only as
substrates for PLC signaling but also as mediators in the
phosphatidylinositol-3-kinase (PI3K)/Akt signaling cascades. It is conceivable, therefore, that an acute molecular
action of antidepressant agents that conserves or supplements cellular PIs could ultimately contribute to the therapeutic mechanism of these medications in depression.

Results
Chemically diverse antidepressant agents increase CDPdiacylglycerol production
Diacylglycerol released from phospholipid breakdown is
normally rapidly phosphorylated to produce phosphatidic acid. In the presence of [3H]cytidine-labeled CTP,
however, the phosphatidic acid is converted to radiolabeled CDP-DG, which can be extracted and separated
away from other labeled metabolites and subsequently
quantified. In the present study, rat brain cerebrocortical,
hippocampal, and striatal slices prelabeled with [3H]cytidine were incubated with various concentrations of
selected antidepressant agents in the presence of LiCl, and
the yield of CDP-diacylglycerol analyzed. Data for each
drug were separately analyzed before they were normalized and collated together for graphical presentation as
shown. The classical antidepressants imipramine and
desipramine, the selective serotonin reuptake inhibitors
fluoxetine and paroxetine, and the atypical agents maprotiline and nomifensine, each significantly and dosedependently enhanced the accumulation of [3H]CDP-DG
in rat hippocampal, prefrontal cortical, and striatal slices
(Figure 1). While concentrations ranging from 0.1 to 1000
μM were tested, only those concentrations lying between
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Figure
Effects of1 classic antidepressants on [3H]CDP-diacylglycerol accumulation
Effects of classic antidepressants on [3H]CDP-diacylglycerol accumulation. Tissue slices prepared from indicated
brain regions were prelabeled with [3H]cytidine and incubated with various concentrations of either imipramine (IMI),
desipramine (DES), fluoxetine (FLU), paroxetine (PAR), maprotiline (MAP), or nomifensine (NOM). After 90 min, tissue contents of [3H]CDP-diacylglycerol were assayed. Each bar is the mean ± SEM (N = 9). Each drug stimulated significant concentration-dependent accumulations of CDP-diacylglycerol (ANOVA, p < 0.001 for each drug). Based on posthoc Dunnett tests, all
agents induced statistically significant CDP-diacylglycerol responses at the 3 or 10 μM concentrations, except for paroxetine in
the hippocampus and imipramine in the striatum where the drug effects were not significant until the 30 μM and higher concentrations.
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the minimal that gave statistically significant effects for
any agent (1–3 μM) and the maximally effective concentrations (100 – 500 μM) are shown. Statistically significant effects were obtained at concentrations as low as
3–10 μM in the hippocampus or prefrontal cortex, while
maximal effects were achieved at the 100 μM concentration of fluoxetine or 300 μM concentrations of most other
agents. For all agents, test concentrations greater than 300
μM resulted in CDP-DG effects that were either statistically similar to, or significantly lower than, the effects
observed at 100 μM for fluoxetine or 300 μM for the other
agents. This reduction in response with increasing concentration after attaining maximal responses was more apparent with the SSRIs, fluoxetine and paroxetine, than with
the tricyclic agents.
Among the brain regions, the hippocampus appeared to
be more sensitive (greater response magnitudes at lower
concentrations), whereas the striatum gave slightly more
robust (maximally attained) effects. The drug responses
were statistically dose-dependent for all effective agents in
each tissue, but there were noticeable differences in
potency or efficacy among the compounds as shown in
the data. Thus, diverse antidepressant agents can acutely
induce CDP-DG synthesis in depression-relevant regions
of the rat brain.
Antidepressant-induced CDP-diacylglycerol formation
translates into increased PI synthesis
To test if the antidepressant-enhanced CDP-DG translates
into increased synthesis of the PIs, brain slice preparations
were labeled with [3H] inositol and incubated in the presence of various antidepressant agents. Results of the subsequent uptake and conversion of [3H] inositol into
inositol phospholipids are shown in Figure 2. Imipramine, desipramine, fluoxetine, paroxetine, and
maprotiline each significantly increased [3H]inositol labeling of PIs in the tested brain regions (Figure 2). Thus, the
increased mobilization or recapture of CDP-DG by the
antidepressant agents translates into increased regeneration of PI signaling substrates.
Effects of monoamine oxidase inhibiting agents CDPdiacylglycerol formation and PI synthesis
Similar to the effects exhibited by the classical antidepressant agents, the monoamine oxidase inhibitors (MAOIs),
phenelzine and hydralazine, produced robust effects on
CDP-DG accumulation in frontal cortex slices (Figure 3),
while tranylcypromine had statistically significant but
rather modest effects (data not shown). While the effects
of phenelzine achieved significance at 1 μM (Dunnett's, p
< 0.01), those of hydralazine became significant at the 10
μM and higher concentrations. Conversely, no significant
effects were observed with several other tested MAOIs,
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namely, pargyline, selegiline, quinacrine, or clorgyline
(Table 1).
MAOIs that were effective in inducing CDP-DG production also showed enhanced effects on PI resynthesis (Figure 3), whereas other MAOIs that were ineffective on
CDP-DG were equally ineffective in increasing PI resynthesis (data not shown). The MAOI data (Figure 3) also
depict the significantly greater relative accumulation of
PIs compared to the accumulation of CDP-DG, implying
the conversion of CDP-DG to PI may be a dynamic or
cumulative process.
We also tested a range of other psychotropic compounds
in order to estimate the extent to which the CDP-DG
response may characterize compounds with antidepressive activity. Neither the antipsychotic agents sulpiride,
chlorpromazine and haloperidol, nor various other psychotropic compounds induced any significant effects on
CDP-DG production (Table 1).
Antidepressant Agents Generally Enhance Inositol
Phosphate Accumulation
To test if resynthesized PIs might contribute to enhanced
IP accumulation, agents tested for effects on CDP-DG
were also tested in a standard IP assay. Across a concentration range of 3–300 μM, imipramine, desipramine, fluoxetine, paroxetine, and maprotiline significantly and dosedependently stimulated the accumulation of IPs in each
brain region (Figure 4). Significant drug effects were generally evident at concentrations of 3–10 μM, while maximal effects were observed at 100–300 μM. With
imipramine tested in the hippocampus and striatum as
the only possible exceptions, test concentrations greater
than 300 μM resulted in IP effects that were either statistically similar to, or significantly lower than, the effects
observed at the corresponding 300 μM concentration. In
general, drug concentrations greater than 300–500 μM
were associated with IP levels that were significantly lower
than effects at 100–300 μM concentrations, possibly
reflecting toxicity from excessive stimulation.
Antidepressant-induced CDP-diacylglycerol formation
partially depends on PI hydrolysis
Phosphoinositide hydrolysis is a major source, but not the
only possible source, of diacylglycerol in the cell. To estimate the extent to which antidepressant-enhanced CDPDG may derive from PI breakdown, we blocked PI hydrolysis and then measured the consequent effects on the ability of antidepressant agents to induce CDP-DG
accumulation. First, we tested the effects of the general PI
metabolism inhibitor, neomycin, against the maximally
effective concentrations of the selected antidepressant
agents. Neomycin concentration-dependently blocked
the effects of imipramine, desipramine, fluoxetine, parox-
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Figure
Effects of2 various classic antidepressants on [3H]phosphatidylinositide synthesis
Effects of various classic antidepressants on [3H]phosphatidylinositide synthesis. Tissue slices prepared from indicated brain regions and prelabeled with [3H]inositol were incubated with various concentrations of either imipramine (IMI),
desipramine (DES), fluoxetine (FLU), paroxetine (PAR), or maprotiline (MAP). After 90 min, [3H]inositol phospholipids were
extracted and assayed as a total pool of extractable phosphatidylinositides. Each bar is the mean ± SEM (N = 9). Each drug
stimulated significant and concentration-dependent increases in [3H]inositol phospholipid synthesis (ANOVA, p < 0.001 for
each drug). From the subsequent posthoc Dunnett tests, all agents induced statistically significant CDP-diacylglycerol responses
at the 3 or 10 μM and higher concentrations.
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Table 1: Psychotropic agents lacking effects on CDPdiacylglycerol accumulation in rat cerebrocortical slices. Agents
were tested at multiple concentrations ranging from 0.1–300 μM.
Data from up to three separate runs were normalized and
pooled for analysis by One-Way ANOVA. None of these
compounds showed significant or concentration-related effects
on CDP-diacylglycerol.

Effects
cylglycerol
Figure
of3 the
accumulation
monoamineand
oxidase
phosphatidylinositide
inhibitors on [3H]CDP-diasynthesis
Effects of the monoamine oxidase inhibitors on
[3H]CDP-diacylglycerol accumulation and phosphatidylinositide synthesis. Cortical slices were tested with
indicated concentrations of phenelzine or hydralazine. CDPdiacylglycerol (CDP-DG) levels were analyzed as outlined
under Figure 1, while phosphatidylinositide (PI) synthesis was
measured as the total pool of extractable [3H]inositol-labeled
phospholipids as in Figure 2. Each point is the mean ± SEM
(N = 9). Each drug stimulated significant concentrationdependent accumulations of CDP-diacylglycerol (ANOVA, p
< 0.001 for each drug) and phosphatidylinositide synthesis
(ANOVA, p < 0.001 for each drug). Note that if individually
compared to the corresponding control measure, each of the
tested concentrations from 0.1 – 300 μM gave statistically
significant effects on CDP-DG and PIs. Note also the greater
relative accumulation of PIs compared to the accumulation of
CDP-DG.

Antipsychotics

MAOIs

Anticonvulsants/Anxiolytics/Others

Chlorpromazine
Haloperidol
Sulpiride
Flupenthixol

Hydroxylamine
Selegiline
Pargyline
Quinacrine

Benztropine
Phenytoin
Diazepam
Nitrazepam

Phenylephrine
Phenobarbital
Chlordiazepoxide

etine, maprotiline, or nomifensine on CDP-DG production (Figure 5A), PI resynthesis (Figure 5B) or IP
accumulation (data not shown) in hippocampal or prefrontal cortical brain slices. Increasing concentrations of
neomycin produced complete blockade of both CDP-DG
and PI responses. We next tested the effects of the selective
PLC inhibitor, U73122, on the drug responses. As shown
in Figure 6, U73122 by itself did not significantly alter
basal CDP-DG production (Figure 6A) or IP accumulation
(Figure 6B), although a slight increase in IP was consistently noted. At concentrations ranging from 0.1 to 10 μM,
U73122 significantly reduced, but was unable to completely block, antidepressant drug effects on CDP-DG production. Conversely, the PLC inhibitor completely
blocked IP stimulation by 100 μM fluoxetine or 300 μM
concentrations of imipramine, paroxetine, maprotiline,
or nomifensine in hippocampal or cortical slices. To validate the effects of U73122, we also tested the compound
against the action of SKF38393, a D1 receptor agonist that
is known to induce PI hydrolysis in these brain tissues
[14,65]. SKF38393-induced IP accumulation was blocked
by U73122 with similar efficacies to the inhibition of the
antidepressant responses (Figure 6B). Moreover, U73123,
an analog of U73122 that is ineffective in blocking PLC
activity, was without effect on any of the CDP-DG or IP
responses (data not shown). The effects of the SSRIs fluoxetine and paroxetine were more sensitive to inhibition by
U73122 than the effects of the tricyclic agents.
Lithium is not required for antidepressant drug effects on
CDP-diacylglycerol
Our initial experiments were designed to compare antidepressant drug effects on the IP and diacylglycerol arms of
the inositol cycle. Thus, it was necessary to include LiCl in
all test incubations, seeing Li+ is needed to block inositol
monophosphatase and thereby enable the accumulation
of released IPs to measurable levels. But, is the presence of
Li+ necessary to demonstrate antidepressant drug effects
on CDP-DG? To answer this question we performed additional experiments in which selected antidepressant
agents were tested for effects on CDP-DG in the absence
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Effects
Figureof4 diverse antidepressants on [3H]inositol phosphate accumulation
Effects of diverse antidepressants on [3H]inositol phosphate accumulation. Experiments were conducted as outlined in the legend to Figure 2, except that tissue contents of [3H]inositol phosphates were assayed by Dowex anion exchange
chromatography as detailed in Methods. Each bar is the mean ± SEM (N = 9). Each antidepressant agent stimulated significant
concentration-dependent accumulations of inositol phosphate (ANOVA, p < 0.001 for each drug).
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Figure 5 of antidepressant-induced [3H]CDP-diacylglycerol production and phosphoinositide synthesis by neomycin
Inhibition
Inhibition of antidepressant-induced [3H]CDP-diacylglycerol production and phosphoinositide synthesis by
neomycin. Slices of rat prefrontal cortex or hippocampus prepared from the same rats were pre-labeled in parallel with
[3H]cytidine or [3H]inositol and incubated with indicated concentrations of neomycin, followed by addition of 100 μM fluoxetine (FLU) or 300 μM imipramine (IMI), desipramine (DES), paroxetine (PAR), maprotiline (MAP), or nomifensine (NOM).
Accumulated [3H]CDP-diacylglycerol (A) or [3H]phosphoinositides (B) were measured after 90 min. While only the hippocampus data are shown for CDP-diacylglycerol and the cortical data for phosphatidylinositides, each analyte was assessed in
each brain region with similar results. Each bar is the mean ± SEM (n = 6). Neomycin significantly and concentration-dependently inhibited drug-induced [3H]CDP-diacylglycerol production and [3H]inositol phospholipid synthesis (ANOVA, p < 0.01 for
each drug). The effects of neomycin alone on CDP-diacylglycerol were not significant, whereas it exerted a slight but significant
increase at the 0.3 mM concentration (Dunett's, p < 0.01) and decrease at the 3 mM concentration (Dunnett, p < 0.01) in
[3H]phosphatidylinositide levels. #p < 0.05; *p < 0.05, compared to respective effects of antidepressant alone by Dunnett test.

or presence of 5 mM LiCl. As shown in Figure 7, LiCl did
not significantly enhance or inhibit antidepressant druginduced CDP-DG production, implying that the presence
of Li+ is not necessary to demonstrate the enhancing
effects of antidepressant agents on CDP-DG production.

Antidepressants elicit greater stimulation of CDPdiacylglycerol production than IP formation
To determine if antidepressant agents exert differential
effects on CDP-DG production compared to PI hydrolysis,
we examined the ratios of CDP-DG production relative to
the IPs (CDP-DG/IP ratio) in corresponding treatment
conditions. The ratios were calculated from the data in
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mulation
Effects
Figure
of6 the PLC inhibitor U73122 on antidepressant-mediated CDP-diacylglycerol production and inositol phosphate accuEffects of the PLC inhibitor U73122 on antidepressant-mediated CDP-diacylglycerol production and inositol
phosphate accumulation. Cerebrocortical or hippocampal slices labeled with either [3H]inositol or [3H]cytidine were incubated in parallel with buffer alone or the indicated concentrations of U73122, followed by addition of 100 μM fluoxetine (FLU)
or 300 μM imipramine (IMI), paroxetine (PAR), maprotiline (MAP), nomifensine (NOM), or SKF38393 (SKF) as indicated.
Accumulated [3H]CDP-diacylglycerol (A) or [3H]inositol phosphates (B) were determined after 90 min. While only the hippocampus data are shown for inositol phosphates and the cortical data for CDP-diacylglycerol, each analyte was assessed in
each brain region with similar results. Each bar is the mean ± SEM (n = 6). U73122 completely blocked [3H]inositol phosphate
accumulation stimulated by either antidepressant agent (ANOVA, p < 0.001). Conversely, U73122 only partially reduced antidepressant drug-induced [3H]CDP-diacylglycerol production. The phospholipase C inhibitor by itself showed slight but significant effects on either analyte. *p < 0.01 compared to effects of antidepressant alone (Dunnett test).

Figures 1, 2, 3, 4 and the results are shown in Figure 8.
With each antidepressant agent, the CDP-DG/IP ratios
increased significantly with increasing drug concentrations. This was true for different classes of drugs, including
the MAOIs phenelzine and hydralazine.

Monoamine receptor agonists exert divergent effects on
CDP-diacylglycerol
In attempts to determine which, if any, of the endogenous
monoaminergic systems may show similar profiles of
CDP-DG/IP effects, additional experiments were conducted with agonists that act directly at PLC-coupled
monoaminergic receptors: α-methylserotonin (5HT2 serotonergic), carbachol (muscarinic cholinergic), SKF38393
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changes between CDP-DG and the inositides, except for
the dopamine agonist which, like the antidepressants,
induced proportionately greater production of CDP-DG
relative to inositide derivatives.

Discussion

Figure
lycerol
production
7 LiCl on antidepressant-induced [3H]CDP-diacylgEffects of
Effects of LiCl on antidepressant-induced [3H]CDPdiacylglycerol production. Slices of prefrontal cortical or
hippocampal tissues were labeled with [3H]cytidine and incubated in the presence or absence of 5 mM LiCl. Indicated
concentrations of fluoxetine or imipramine were added, and
after 60 min accumulated [3H]CDP-diacylglycerol was measured. While the frontal cortex data are shown, similar observations were made in the hippocampus. Each bar is the mean
± SEM (n = 6). The presence of LiCl did not significantly alter
the stimulatory effects of fluoxetine or imipramine on
[3H]DCP- diacylglycerol accumulation (ANOVA, p > 0.05).

(D1-like dopaminergic), and phenylephrine (alphaadrenergic). Corresponding CDP-DG ratios were calculated as for the antidepressant agents. As shown, α-methylserotonin, carbachol, phenylephrine (Figure 9) or
SKF38393 (Figure 10) significantly increased IP accumulation and CDP-DG production in frontal cortex or hippocampal tissues. Carbachol failed to increase PI
synthesis, SKF38393 significantly enhanced PI synthesis,
while the other two agents had significant but relatively
small effects on PI. The ratios of CDP-DG production relative to IP accumulation are shown in the corresponding
right panels of Figure 9 and Figure 10. With both carbachol and phenylephrine, there was a dramatic decrease in
the CDP-DG/IP ratio. While the ratio did not decrease as
much for α-methylserotonin, there was no concentrationrelated increase either. Conversely, SKF38393 increased
CDP-DG/IP ratios significantly and in a manner similar to
the antidepressants (Figure 10). Indeed, even the ratios of
CDP-DG relative to PIs or the combination of both inositol derivatives (CDP-DG/IP&PI) were significantly
enhanced. Thus, agonists at the direct PLC-coupled
monoamine receptors showed parallel and corresponding

Various experimental approaches have been used in the
past to demonstrate positive effects of select antidepressant agents on the IP arm of PI signaling cascades
[15,27,30,66]. The present data demonstrate for the first
time that antidepressant agents could increase by severalfold the production of CDP-diacylglycerol, a crucial signaling intermediate that is both a derivative of diacylglycerol and a precursor for the biosynthesis of PIs. This effect
appeared to be common across agents from diverse chemical and pharmacological classes, seeing it was obtained
with the tricyclics imipramine and desipramine, the SSRIs
fluoxetine and paroxetine, the atypicals maprotiline and
nomifensine, and the MAO inhibitors phenelzine and
hydralazine. Thus, the findings could point to a mechanism (enhanced phospholipid biosynthesis) and mediator (CDP-diacylglycerol) for the biochemical and possibly
clinical effects that may be common across diverse classes
of antidepressants.
Earlier studies observed that several antidepressants
enhanced [3H]IP accumulation and [3H]PI labeling in rat
cortical slices [27,29]. The mechanism of this response
was confounding, seeing other studies that directly
assayed phospholipase C activity suggested that the drugs
could stimulate or inhibit PLC-mediated PI hydrolysis
[15,24]. In the present study, the antidepressants were
equally effective in enhancing CDP-DG in the presence or
absence of LiCl, whereas the presence of Li+ was necessary
to demonstrate the effects of the drugs on IP accumulation. This implies that the compounds do not inhibit IP
breakdown (otherwise they would have substituted for
Li+), and that their effects on IP accumulation is probably
secondary and passive to the enhanced production of
upstream CDP-DG and PI substrates.
Numerous agents acting at diverse receptor systems can
enhance PI metabolism, but few such pure receptor agonists are known to exhibit an antidepressive effect in
humans or animals [67]. How then might an effect of
antidepressant agents on CDP-DG and PI synthesis be
associated with the antidepressive efficacy of the compounds? An attempt to address this question led to comparisons of the ratio data between the antidepressants as a
group and agonists at alpha-adrenergic, 5HT2 serotonergic, and dopaminergic receptors (which are implicated in
depression) as well as the muscarinic cholinergic receptor
that is not known to contribute to the actions of antidepressant agents. While all these receptors are coupled to PI
hydrolysis, only some 5HT2 agonists and SKF38393 have
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Ratios
Figureof8 antidepressant-induced CDP-diacylglycerol versus inositol phosphates
Ratios of antidepressant-induced CDP-diacylglycerol versus inositol phosphates. The data in Figures 1-4 were recalculated by dividing the CDP- diacylglycerol effects of each concentration of each antidepressant agent by the corresponding
effects of the agent on inositol phosphate accumulation to yield the CDP- diacylglycerol/inositol phosphate (CDP-DG/IP) ratios
shown. To facilitate merging of data from multiple experiments, these values were converted to percentages relative to the
ratio values in the respective control samples and then averaged to give the mean ± SEM shown for the classic agents (A),
phenelzine (B), and hydralazine (C). Data for the hippocampus are shown, but similar observations were made in the cortical
tissues. Data for each agent were analyzed by One-way ANOVA followed by posthoc Dunnett tests. #p < 0.05; *p < 0.01; compared to the respective control (zero drug concentration).

been shown to elicit antidepressive effects in rodent models [67-69]. The ratio of CDP-DG to IP components for
phenylephrine and carbachol decreased, for α-methylserotonin remained unchanged, and for SKF38393
increased, with increasing concentrations of agonist. For
the antidepressant agents, the ratios were not only significantly elevated, but actually increased in a concentrationdependent fashion. This was true of all classes of antidepressants examined, including the effective members
among the MAO inhibitors. The similarity between the
effects of SKF38393 and the antidepressants may underlie
the behavioral antidepressant efficacy of the compound as

previously demonstrated in the rodent model [69].
Hence, to the extent that CDP-DG production might be
relevant to depression or the mechanism of antidepressant drug action, an antidepressive agent should not
merely increase PI hydrolysis, but the CDP-DG produced
must exceed and probably precede the production of PI
messengers.
It was noteworthy that even the SSRIs produced significant increases in each CDP-DG ratio, whereas the direct
5HT2 agonist α-methylserotonin did not. If the biological
actions of the SSRIs were limited to the actions of the
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Figure
Effects
and
phosphatidylinositide
of9 α-methylserotonin,
synthesis
carbachol, and phenylephrine on CDP-diacylglycerol production, inositol phosphate accumulation
Effects of α-methylserotonin, carbachol, and phenylephrine on CDP-diacylglycerol production, inositol phosphate accumulation and phosphatidylinositide synthesis. Slices of prefrontal cortical or hippocampal tissues were prelabeled with [3H]cytidine or [3H]inositol in parallel, and then incubated in the presence of 5 mM LiCl. Indicated concentrations
of the agonists were added for 90 min, followed by assay of the levels of [3H]CDP- diacylglycerol, [3H]inositol phosphates, and
[3H]phosphoinositides. Calculated ratios of CDP- diacylglycerol over inositol phosphates (CDP-DG/IP ratios) are shown in the
rightmost panel relative to the scale on the right y-axis. Each bar is the mean ± SEM (n = 15 for α-methylserotonin, 12 for carbachol, 9 for phenylephrine). Data were separately analyzed by One-way ANOVA for each receptor agonist. *p < 0.01, Dunnett test compared to the respective control (zero drug concentration).
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Effects
Figureof10SKF38393 on CDP-diacylglycerol production, inositol phosphate accumulation and phosphatidylinositide synthesis
Effects of SKF38393 on CDP-diacylglycerol production, inositol phosphate accumulation and phosphatidylinositide synthesis. Prefrontal cortical slices pre-labeled with [3H]cytidine or [3H]inositol in parallel were incubated with indicated concentrations of SKF38393 in the presence of 5 mM LiCl for 90 min, followed by assay of [3H]CDP-diacylglycerol (A),
[3H]phosphoinositides (B) and [3H]inositol phosphates (C). Calculated ratios of CDP-diacylglycerol over inositol phosphates
(CDP-DG/IP ratio), phosphatidylinositides (CDP-DG/PI ratio), or the sum of the inositol phosphates and phosphatidylinositides (CDP-DG/IPPI ratio) are shown in the right panel (D-E, respectively). Each bar is the mean ± SEM (n = 12). Data
were analyzed by One-way ANOVA and posthoc Dunnett tests. #p < 0.05; *p < 0.01, compared to the respective control by
Dunnett test.
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drugs to enhance synaptic serotonin levels, then one
would expect direct serotonin receptor stimulation to
elicit similar effects. This disparity should suggest that
facilitation of synaptic serotonin levels may not be the
sole or sufficient mechanism of action of the SSRIs.
Rather, antidepressant-enhanced synaptic serotonin may
work in concert with antidepressant-facilitated neurolipid
biosynthesis to achieve the type and level of downstream
signaling responses that may contribute to the antidepressive effect.
Although CDP-DG production induced by the antidepressants may be derived from phosphoinositide breakdown,
it is not impossible that the CDP-DG pool may be generated from additional endogenous sources. In an initial
attempt to address this, we observed that antidepressantmediated accumulation of [3H]CDP-DG was completely
blocked by the non-specific phosphoinositide inhibitor,
neomycin, in prefrontal or hippocampal tissues. Conversely, the selective PLC inhibitor U73122 could only
partially decrease CDP-DG production, while it completely blocked the release of IPs. These results suggest
that, while the integrity of the phosphoinositide pool is
essential to the full effect of antidepressant agents on
CDP-DG (based on the neomycin data), the PLC-accessible pool of phosphoinositides may not be the only source
of antidepressant-mediated CDP-DG production (based
on the U73122 data). It is known that neural (and other)
cells maintain multiple pools of phosphoinositides not
all of which may be accessible to PLC-mediated cycling.
The possibility that the antidepressants could mobilize
these additional reserves of PI substrates, particularly following acute or chronic metabolic depletion of the substrates, should be an interesting subject for future
investigations.
A critical question that was also attempted relates to the
extent to which the CDP-DG response may be specific to
antidepressant agents versus other psychotropic drugs.
After testing a wide range of compounds, we observed that
neither the antipsychotics chlorpromazine and haloperidol, nor several other psychotropic agents were capable of
inducing the degree of CDP-DG effects observed with the
antidepressant agents. While this suggests that the CDPDG effect, particularly the dose-related effect on CDP-DG/
IP ratio, could reflect a characteristic property of antidepressant medications, we were equally surprised by the
disparity in efficacy among the MAO inhibitors. The ineffective agents included the nonselective MAO A/B inhibitor clorgyline, and the selective MAO-B inhibitors
pargyline and selegiline. At least one of these, clorgyline,
is used clinically for the treatment of depression. Conversely, other MAO inhibitors, including phenelzine,
hydralazine and tranylcypromine were significantly effective in inducing CDP-DG. The chemical or biological
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basis for this disparity among the MAOIs is still unclear.
Indeed, considering the relatively marked effects of
phenelzine and hydralazine, it is possible that inhibition
of MAO-mediated monoamine breakdown may not be
the predominant mechanism by which these compounds
modulate CDP-DG signaling.
It remains to be determined how the present in vitro observations may relate to in vivo drug concentrations or behavioral effects. While all tested antidepressants generally
induced significant CDP-DG or PI effects at concentrations of 1–10 μM (and as low as 0.1–0.3 μM for
phenelzine and hydralazine), the in vivo concentrations
or doses needed to induce comparable effects have not
been determined. Nevertheless, a recent report suggests
that antidepressants may induce in vivo CDP-DG or phosphoinositide effects at doses commonly used to elicit antidepressant-like behaviors in animal models [70].
Additional studies should help to clarify these questions.

Conclusion
Collectively, the present data raise the speculation that
depression may be associated with decreased turnover or
biological efficacy of phosphoinositide-related signaling
systems, possibly due to depletion of phosphoinositide
substrates. Antidepressants may act by mobilizing CDPDG to help replenish or supplement the pool of available
PIs. In addition to PLC-mediated cascades, phosphatidylinositol is a key substrate for the PI3K signaling pathway
[71]. Earlier reports showed that PI3K signaling is relevant
to the induction of neurogenesis or neuronal survival and
plasticity [72,73]. A recent study determined that the
activity of PI3K and its downstream target, Akt, is
decreased in postmortem brain tissues of depressed suicide victims [74]. Extensive interactions or crosstalk exists
among downstream mediators of the PLC and PI3K systems and other signaling pathways that have been implicated in depression. Thus, it is conceivable that an early
action of antidepressant agents to enhance the mobilization of CDP-DG could lead to coordinate effects on multiple signaling systems, which might then explain the
various molecular, structural, and functional effects of the
drugs. The data, however, do not exclude the possibility
that multiple signaling pathways, including the adenylyl
cyclase pathway, may be involved in depression or the
mechanism of action of antidepressant agents. Nor do the
data directly address the conventional notion that antidepressive medications need be administered chronically in
order to elicit a clinical effect. Additional studies also are
required before a model could emerge that might relate
these findings to the various theories of depression or
antidepressant mechanisms. Notwithstanding these
pending questions, the present CDP-DG findings demonstrate a functional biochemical response that is common
across divergent antidepressant classes, is elicited within
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the time frame that the drug is available to the tissues, and
may have a plausible role in the pathology of depression
or the mechanism of action of current antidepressive
agents.

Methods
Animals
Male Sprague-Dawley rats weighing 225–250 g were
obtained from Zivic Laboratories (Zelienople, PA) and
housed in climate-controlled facilities with a 12-h light/
dark cycle for at least 3 days before use. The animals were
caged in groups of three and allowed free access to food
and water. Protocols for the care and use of the experimental animals were approved by the Institutional Animal Care and Use Committee and conformed to the
National Institutes of Health Guide for the Care and Use
of Laboratory Animals.
Drugs and chemicals
Antidepressant compounds and buffer reagents were purchased from Sigma-Aldrich (St. Louis, MO). SKF38393
was a gift from the NIMH Chemical Synthesis Program
(NIMH, Bethesda, US). Nomifensine was first dissolved in
0.2% tartaric acid and SKF38393 in distilled water before
either drug was diluted to use concentrations in assay
buffer. Other drugs were prepared fresh in HEPES bicarbonate assay buffer (HBB) [65]. Each experiment was performed on multiple occasions using fresh preparations of
drugs. Protein was assayed by the Bradford method using
BioRad protein assay reagents (BioRad, Hercules, CA).
Measurement of CDP-diacylglycerol accumulation
Accumulation of CDP-diacylglycerol was measured in
brain slice preparations by taking advantage of the CTPphosphatidate transfer reaction as previously described in
detail [75-77]. Briefly, male Sprague-Dawley rats weighing
between 225 and 300 g were rapidly decapitated and the
brains removed and rinsed in calcium-free HBB [75,78].
Brain regions of interest, including the prefrontal cortex,
hippocampus, and striatum, were quickly dissected out
and 350 μm prisms prepared using a McIlwain tissue
chopper [78]. The slices were washed with calcium-free
HBB and pre-incubated for 45 minutes at 37°C. Slice aliquots of approximately 300 μg protein were then incubated
with 1.5 μCi of 5- [3H]cytidine (20 Ci/mmol; American
Radiolabeled Chemicals, St. Louis, MO) in order to generate an endogenous pool of radiolabeled cytidine triphosphate (CTP) for feeding into the CTP:phosphatidate
transfer reaction [75]. Following addition of 5 mM LiCl,
test drugs or buffer were added for a total volume of 250
μl, and incubation continued for 60 or 90 min as indicated. Reactions were terminated by addition of 1.5 ml
chloroform-methanol-1M HCl (100:200:1). Formed lipids were extracted by liquid partitioning in chloroform
followed by centrifugation at 1000 × g for 5 min in order
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to separate the liquid phases. Aliquots of the organic
phase were quantitatively transferred into scintillation
vials, dried at room temperature, and redissolved in
Biosafe scintillation cocktail. Radioactivity in this lipid
fraction was determined by liquid scintillation spectrometry; this activity corresponds to [3H]CDP-DG as previously indicated [63,75,79], and confirmed by us through
thin layer chromatographic analysis of the reaction products (unpublished observations).
Measurement of inositol phospholipid resynthesis
Brain tissues were prepared and incubated as described
above for assaying CDP-DG, except that 1.5 μCi of
[3H]inositol (20 Ci/mmol; American Radiolabeled Chemicals, St. Louis, MO) was used instead of [3H]cytidine to
label the slices. Following the labeling incubation, drugs
were added and allowed to act for 60 or 90 min as indicated. Samples were extracted with chloroform-methanol1M HCl (100:200:1), partitioned with chloroform into
aqueous and organic phases, and aliquots of the organic
phase dried and assessed for radioactivity that corresponded to the inositol phospholipids. For purposes of
the present study, it was not necessary to attempt to separate the multiple phosphorylated or isomeric forms of
these phospholipids. Hence, the data potentially represent the mix of phosphatidylinositol, phosphatidylinositol-4-phosphate,
and
phosphatidylinositol
4,5bisphosphate in any of their positional isomeric forms.
Based on the levels of the phospholipids present at the
start of drug treatment, a subsequent decrease is seen as
depletion, whereas an increase in the [3H]inositol-labeled
pool of the phospholipids is considered to represent further phospholipid synthesis or resynthesis [76,80].
Measurement of inositol phosphate accumulation
To measure the levels of IPs formed, tissues were treated
exactly as in the foregoing PI synthesis assays, including
the use of [3H]inositol for prelabeling of the PI pool. The
250 μl reactions were terminated by mixing the samples
with 1.5 ml of chloroform – methanol – 1 M HCl
(100:200:1). Following chloroform-mediated partitioning of the extracts as described [65], aliquots of the aqueous phase were analyzed for the content of [3H]IPs by
Dowex anion exchange chromatography [65,78]. An IP
fraction was collected from the eluate and the solution
converted into a gel by use of Scintisafe Gel (Fisher Scientific, Pittsburgh, PA). The amounts of IP-associated radioactivity in the samples were then measured by liquid
scintillation spectrometry.
Data analysis
Data from the various experiments were normalized relative to the respective control or basal measurements, and
then pooled for analysis. Data were tested by an appropriate analysis of variance (ANOVA) using SPSS software
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(SPSS, Chicago, IL, USA). Where warranted, the ANOVAs
were followed by post hoc analyses using the Dunnett test
to compare various treatment means to their respective
controls. Statistical comparisons were considered significant at p < 0.05 or better.
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